← Back to Team

Tim Schmidt

Head of Translational Research

Tim joined Sitryx in November 2019 as Head of Translational Research, with over 14 years of drug development experience in the Translational Research and Early Clinical Development space and a demonstrated history of successfully progressing several new therapeutic entities into Ph1 and 2 clinical trials. Having formerly held positions as Translational Sciences Manager at (GSK, UK), Director Clinical Strategy (UCB Celltech, UK) and most recently Chief Translational Research Officer (TxCell, France), Tim has over the years successfully lead the conception and implementation of biology and translational research strategies as well as the delivery of clinical and regulatory packages for several successful regulatory submissions. Most recently he drove the transitioning of the French biotech TxCell from research to clinical development stage, resulting in the successful acquisition by Sangamo Therapeutics for a cash equivalent of approximately $84 million and progression of the world-first autologous CAR-Treg cell therapy Tx200 into clinical testing.

Tim obtained degrees from Ruprecht Karls University in Heidelberg (BSc) and University College London (PhD) prior to postdoctoral studies at the University of Oxford